---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-138253"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:07:16.651354+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation

## Summary
- Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.
- FDA granted RMAT designation for TSHA-102 for Rett syndrome based on early safety/efficacy data.
- Completed low-dose cohort in REVEAL adult trial; enrolled first patient in high-dose (1x10^15 vg) for Q2 dosing.
- Second pediatric patient dosed in low-dose cohort; initial data from both trials expected mid-2024.
- Cash $124M; expects to fund operations into 2026.

## SEC filing metadata
- accession: 0001193125-24-138253
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/0001193125-24-138253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/d833929d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-138253
- JSON: https://secwatch.observer/filing/0001193125-24-138253.json
- Plain text: https://secwatch.observer/filing/0001193125-24-138253.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/0001193125-24-138253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.